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Introduction
Chimeric antigen receptors (CARs) were engineered by Gross et al., 1 who first generated and expressed the chimeric T-cell receptor (TCR), which is composed of the TCR constant domains and variable domains of the antibody, and these chimeric genes are non-MHC-restricted. A specific single chain fragment variable (scFv) from anti-tumorassociated antigen (TAA) antibody was fused to T-cell activation-related domains and was expressed on membrane of the cells. 2 As a result, the T cells display tumor-targeted cytotoxic activity and the ability to proliferate sustainably. Subsequently, a CD19-redirected CAR T cell targeted against B-cell malignancies was developed and clinically tested, and it demonstrated remarkable effectiveness both in children and adult patients. 3, 4 Chimeric antigen receptor T-cell therapy provides a novel treatment choice for blood cancer patients, particularly for relapsed and refractory leukemia.
CD19 is a specifically expressed antigen in the B lymphocyte lineage, maintaining an upregulated expression during the early B-lineage cells to the mature B cell differentiation until final downregulation during terminal differentiation cells, and that CD19 has become a chimeric immunotarget for malignant B cells, including acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphomas (NHL). 5 In addition, another publication revealed an essential role for CD19 in promoting early B-cell activation events in response to membrane-bound ligand stimulation. 6 Therefore, CD19 chimeric antigen receptor therapy in oncology has progressed remarkably in recent years, especially for refractory/relapsed hematological malignancies. 3, 4, [7] [8] [9] Furthermore, a recently modified CAR based on cancer-associated Tn-Glycoform has revealed the effect of CAR T cells on solid cancer. 10 In clinical studies, T cells were collected from a patient with leukapheresis and then isolated and activated with antibodies 11 which induced T cell activation and proliferation, thereby making the cells more likely to be responsible for viral transduction. These transduced cells can be expanded to the required quantity. Quality control and assurance assays are necessary before the prepared T cells can be re-transfused to patients. 12 However, there are many challenges and considerations. For instance, if the dose of infused CAR T cells is insufficient, the expected result may not be achieved; on the other hand, an over-infused dose may cause toxicities mediated by CAR T cells, such as cytokine release syndrome (CRS). 13 An effective method for examining and quantifying the transduced cells could help to accurately control the amount of infused CAR T cells administered to the patient, and could therefore lead to a more effective treatment. Flow cytometry (FCM) is a good choice, but a new set of detection apparatus must be used for each individual patient to protect against cross-infection. The cost of the FCM detection method can be prohibitive.
Green/red fluorescent protein (GFP) has been a useful tool for intracellular study since it was discovered 14 and it is used as a marker for gene expression. 15 These noninvasive and visualization proteins can serve as a marker for quantifying the number of interest infected T cells when administered clinically 16 or can be used to determine the ratio of infected cells to total cells. In addition, an antibiotic-resistance gene used in a recombinant vector is another method of screening for infected cells or valid cells with removing the uninfected cells. However, both approaches have employed exotic genes/proteins which are immunogenic molecules and pose a potential hazard to patients in clinical use. In this study, we fused GFP to CD19 as a fusion protein, expressed it in Escherichia coli and purified it as a probe, so as to examine the infection efficiency of the CD19-directed chimeric antigen receptor on the surface of T cells based antigen-antibody interactions. Positive cells are marked with the GFP-CD19 fusion protein, due to the CD19-directed CAR being expressed on the surface of the infected cells. Valid CAR T cells can be calculated by counting the number of positive cells. Using this method, the number of valid cells can be accurately calculated before being re-transfused to patients.
Material and methods

Cloning of target genes
The CD19 gene and the GFP gene were amplified with polymerase chain reaction (PCR) from cDNA (GeneChem, Shanghai, China) and pET-28b-EGFP plasmid (Dingguo Changsheng, Beijing, China), respectively. The specific DNA primers for CD19 with restriction sites BamHI (upstream) and HindIII (TaKaRa, Osaka, Japan) (downstream) were 5'-AGGATCCGAGGAACCTCTAGTGGTGAAGG-3' (up) and 5'-CAAGCTTTCACCTGGTGCTCCAGGT-GCCC-3' (down). The specific DNA primers for GFP were 5'-GCATATGGTGAGCAAGGGCGAGGAG-3' (up) and 5'-AGGATCCCTTGTACAGCTCGTCCATGCC-3' (down) with restriction sites NdeI and BamHI (TaKaRa) upstream and downstream, respectively. The PCR products were analyzed in 1.0% agarose gel and purified.
Plasmid construction
The target DNA was isolated through electrophoresis in 1.0% agarose gel. In brief, the gels with DNA fragments were excised and purified with a Gel Extraction Kit (Lifefeng, Shanghai, China). These fragments were inserted into pGEM T-Easy plasmid (Promega, Madison, USA) using T/A cloning. The ligation products were transformed into Top10 competent E. coli cells. Following a heat shock, the transformed cells were recovered in super optimal broth with catabolite repression (super optimal catabolite repression (SOC) medium, 2% tryptone, 0.5% yeast extract, 0.05% sodium chloride (NaCl), 2.5 mM potassium chloride (KCl), 10 mM magnesium chloride (MgCl 2 ), and 20 mM glucose) at 37°C for 45 min. Recombinant colonies were cultured in agar plates (1% tryptone, 0.5% yeast extract, 1% NaCl, and 1.5% agar). Notably, the ligation product should be incubated at 70°C for 5 min to inactivate the ligase before the transformation. The recombinant plasmids were extracted from the bacteria and identified using endonuclease analysis. The CD19-T vector recombinant plasmid was identified by BamHI and HindIII, and the GFP-T vector by NdeI and BamHI. The inserted sequences were verified through DNA sequencing (Sangon Biotech, Shanghai, China).
Subsequently, the verified CD19-T vector recombinant plasmid and pCold TF plasmid which contained CspA promoter (a cold promoter, used to induce expression at low temperatures) and an ampicillin-resistance gene were digested by BamHI and HindIII, respectively. Electrophoresis with 1.0% agarose gel was performed. The target CD19 gene fragment and the linearized pCold TF plasmid in the gels were purified and ligated with T4 DNA ligase. The ligation products were transformed into Top10 competent E. coli cells, which were then cultured in agar plates and SOC medium with ampicillin. The reconstructed CD19-pCold TF plasmid was extracted from the bacteria and identified by BamHI and HindIII. Finally, the GFP-T vector recombinant plasmid and this CD19-pCold TF plasmid were digested by NdeI and BamHI, respectively. The GFP gene fragment and CD19-pCold TF plasmid vector were purified and the GFP-CD19-pCold TF recombinant plasmid was constructed through ligation and identified with NdeI and HindIII.
Construction of CD19-CAR lentiviral vector and packaging of lentivirus
The CD19-CAR lentiviral expression plasmid was constructed and the insert included the Kozak sequence, the IL-2 signaling peptide, scFv antibody, Fc hinge, CD28 transmembrane domain, 4-1 BB signaling domain, and CD3 zeta. The scFv antibody fragment is a gift from our colleague Dr. Jianghai Liu (Sichuan University, Chengdu, China), and the rest of the insert was a gift from Dr. Guo's lab (University of Saskatchewan, Saskatoon, Canada). The whole insert was inserted into lentiviral expression vector pCDH-EF1 (no fluorescence). The recombinant vector was identified with XbaI and SalI and verified through sequencing. The lentiviral particles were purchased from Shanghai GenePharma Co. Ltd (Shanghai, China). The final virus titer was 1 × 10 8 TU/mL.
Protein GFP-CD19 expression
The GFP-CD19-pCold TF recombinant plasmid was transformed into BL21(DE3) competent E. coli bacteria for expression. 17 After overnight incubation in agar plates, single colonies were picked from the plates and placed into lysogeny (LB) broth with ampicillin to grow overnight at 37°C in a shaker. This cultured medium was transferred into fresh LB (1:200) with ampicillin in a flask to culture for about 2 h until its OD 600 value was 0.5. The culture was cooled at room temperature. When the temperature of the broth dropped to 15°C, isopropyl-b-D-thiogalactopyranoside (IPTG; Solarbio, Beijing, China) was added into the culture. The final concentration of IPTG in the culture was 0.5 mM and the bacteria were cultured at 15°C for additional 4 h. Cells were harvested using centrifugation at 4000 g at room temperature for 10 min and they appeared to be green under visible light. The harvested cells were stored at −80°C or used immediately.
Protein purification
The cell pellet harvested from 100 mL of the culture described above was re-suspended in 25 mL of phosphatebuffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM disodium phosphate (Na 2 HPO 4 ) and 2 mM monopotassium phosphate (KH 2 PO 4 at a pH of 7.0) with 1 mM of phenylmethylsulfonyl fluoride (PMSF) and 0.5% Triton X-100 (0.5%) on ice. The sample was frozen at −80°C for 30 min and were taken out. After thawing out, it was sonicated at 85 W for 6 s, followed by 7 s on ice in order to shear the DNA for lower viscosity. Sonication and icing were repeated 5-7 times in all samples until the solution was clear. The cell debris was centrifuged at 12,000 g for 10 min at 4°C. The supernatant was then transferred to a new tube. Then, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for the supernatant was performed to figure out the solubility of the protein. The rest of the supernatant was stored at −20°C or on ice for the following step.
Ni-NTA-agarose purification was prepared and 4 mL of Ni-NTA resin (beads) was pipetted into a 10 mL purification column. The resin was washed using 5 column volume (CV) of deionized water and then 5 CV of PBS (pH 7.0) for equilibrium. Twenty-five milliliters of the supernatant was slowly added into the column for binding. The protein in the column was washed with 5 CV of PBS (pH 7.0) and 3 CV of wash buffer (PBS pH 7.0 buffer containing 20 mM imidazole) successively, and eluted with PBS (pH 7.0) with 250 mM of imidazole into a new tube. The resin was again washed with PBS (pH 7.0) with 800 mM of imidazole (3 CV). Finally, the column was washed with PBS (pH 7.0) 5-8 times, with sterile deionized water 3-5 times and washed again with 20 mL of 20% ethanol; then it was filled with 20% alcohol and stored at 4°C. The eluted protein was confirmed using SDS-PAGE analysis. The 250 mM of imidazole was centrifuged at 4500 g for 50 min at 4°C in an ultrafiltration centrifuge tube (Merck Millipore, Billerica, USA), in order to remove small molecular substances and to concentrate the purified protein. This step was repeated and the protein was concentrated to 2.0 μg/mL.
Infection of 3 cell lines
The lentiviral vector was packaged for CD19-CAR expression and the titer was 1 × 10 8 TU/mL (GenePharma). First, the HEK 293 cells (5 × 10 4 /mL) were seeded in 6 of the wells (500 μL each) of a 24-well plate. After the seeded cells were cultured for 12 h, the media were replaced with infection mix. Three of the wells had 490 μL of complete medium, 10 μL of lentivirus and 0.5 μL of polybrene added, with a working concentration of 5 μg/mL for each one. The other 3 control wells had only 500 μL of complete medium added. Daudi cells and Jurkat cells were infected through the same process as the HEK 293 cells, but the method of treating the cells was different. The cells were cultured at 37°C in 5% CO 2 for 72 h. Then, 5 μL of the GFP-CD19 fusion protein was added to each culture (0.2-2.0 μg/mL). Subsequently, the cells were cultured under the same conditions for another 6 h, the media were replaced by PBS and the cells were observed with fluorescence microscope and quantified using cell counting in each chamber.
Results
Plasmid construction
The CD19 gene (coding sequence; 1671bp) and the GFP gene (717bp) were acquired through PCR from commercial cDNA and pET28b-GFP plasmid, respectively, and were identified with 1% agarose gel electrophoresis, as shown in Fig. 1 . Then, the target genes were ligated into T vector. The CD19 gene was identified by BamHI and HindIII. A 1671bp fragment can be seen in Fig. 2A . Similarly, the GFP gene was identified by NdeI and BamHI. A 717bp gene fragment shows correctly in Fig. 2B . Furthermore, the sequencing results of the constructed T vector plasmids were also correct. The CD19 gene was cut and then ligated to pCold TF vector. The recombinant plasmid was identified by BamHI and HindIII. A 1671bp gene fragment and a 5769bp gene fragment can be seen in Fig. 3A . The GFP gene was ligated to this recombinant plasmid and identified by NdeI and BamHI. The 2388bp gene fragment of the CD19-GFP gene and a 5769bp gene fragment of linearized pCold TF plasmid visible in Fig. 3B indicate that the recombinant plasmid was constructed successfully.
Expression and purification of the CD19-GFP fusion protein
The CD19-GFP fusion protein induced by IPTG was expressed in BL21 E. coli bacteria and collected. It was purified using Ni-NTA-agarose purification and concentrated using protein concentrators. The expression and purification results were confirmed using SDS-PAGE (Fig. 4) .
Quantitative analysis of infected efficiency
The CD19-CAR was transduced by lentiviral vector into HEK 293 cells. There was no green or red fluorescence particles visible in the cells which were infected by the lentivirus. Expression of GFP can be detected under a microscope due to the specificity of CAR T cells. The images captured 
Discussion
CD19 mainly expresses on B-lineage cells, which makes it a specific antigen for immunotherapy.
18 CD19-directed CAR T cells against B-cell malignancies provides a novel and effective treatment for patients, particularly for those with relapsed and refractory B-lineage leukemia. [19] [20] [21] [22] Except engineered T cell, CD19-redirected NK92 cells also show a promising result against B-lineage leukemia. 23 In addition, CD19-redirected T memory stem cells represent a potential method for the treatment of B-lineage leukemia. 24 In the process of engineering therapeutic cells, another vector, apart from the lentiviral vector, is also employed to mediate the expression of CAR. 25 Toxicity and the side effects of CD19-directed CAR T cells are increasingly drawing attention to this immunotherapy. The main mechanism of the toxicity and side effects could be attributed to cytokine release, tumor cell lysis, B-cell aplasia, and macrophage-activation syndrome. 26, 27 Although most mild toxicity and side effects are reversible, some severe toxicities need medical treatment. A low dose of engineered cells may not trigger a response of antitumor activity, and an extra dose of immunotherapeutic cells may lead to severe toxicity and side effects. Therefore, administering the appropriate amount of engineered T cells to patients may be the first step in controlling the occurrence of toxicity and side effects. It is widely accepted that a correct dosage of CAR T cells is required for each re-transfusion to patients, 12, 19 so the infection efficiency and the number of valid CAR T cells is accurately calculated before re-transfusion. Due to the alteration of infection efficiency, valid CAR T cells cannot be estimated from the total number of infused cells. In order to track infection efficiency or to screen for valid infected cells by removing uninfected cells, a fluorescence protein gene and a resistant gene are commonly used in molecular manipulation. Valid cells can be counted and calculated before re-transfusion by the former method, and valid cells can be gathered by removing uninfected cells via the latter one. Both methods can provide us with an approach using which we can accurately control the infusion dosage of CAR T cells rather than the number of total cultured cells.
Unfortunately, both proteins are derived from exotic genes and their products carry immunogenicity to acceptors, 28 leading to impairment when these proteins are infused into patients along with CAR T cells. On the other hand, if flow cytometry is employed with an immunofluorescence antibody, it will increase the cost of treatment because each sorting process requires a new set of sorting apparatus. In addition, the application of an immunofluorescence antibody may become a new immunogen, leading to new barriers in the application.
A safe and simple approach is needed in order to quickly determine the infection efficiency and to calculate the number of valid engineered cells in the application. In this study, we fused CD19 to GFP and expressed it in E. coli under a regular molecular biological process. The fusion protein solubility was optimized at 15°C and was purified with Ni-NTA agarose beads. 29 After the target cells (including adherent and suspension cell lines) were infected with lentiviral particles, the purified fusion protein was directly added to the culture medium and left to culture for 6 h. GFP could be directly observed under a microscope and the infected cells (expressing CD-19 CAR) could be determined from other cells (data not shown). The results would become clearer than before when the cultured medium (including CD19-GFP) was removed by washing the cells with a regular culture medium.
Because CD19-GFP (as an antigen) can be recognized by CAR expressed on the surface of the target cells, the fusion protein serves as a probe to visualize the CARexpressing cells. The non-specific binding of CD19-GFP to other proteins is negligible when a fluorescence microscope is used. The ratio of fluorescence cells to total cells can be calculated by determining the number of cells in fluorescence fractions and the number of total cells. In clinical use, the number of valid cells can be accurately administrated to patients. This method provides a novel approach to administrating a dose of CAR T cells in clinical practice using vectors free of the antibiotic-resistance gene and the fluorescence protein gene.
